An Important Message received from Pharmac regarding a Dexamfetamine Brand change, July 2022.
Pharmaceutical supplier API has notified Te Pātaka Whaioranga – Pharmac that they have closed their Auckland manufacturing plant and are withdrawing from the New Zealand market. This was not a decision Pharmac had control over – this was a commercial decision by API.
API supplied around 21 funded medications in New Zealand, including dexamfetamine 5 mg tablets.
We expect stock of the API brand of dexamfetamine to begin running out during August 2022, and people will need to change brands to continue with their treatment. We know that a brand change for this medicine is not ideal. However, our clinical experts have advised us that ongoing supply of dexamfetamine is essential.
What we are doing
Pharmac is working to secure long-term supply of dexamfetamine sulfate 5 mg tablets. We will keep you updated about this, but in the meantime, we are listing a short-term supply of Aspen’s brand of dexamfetamine 5 mg tablets on the Pharmaceutical Schedule from 1 August 2022.
This brand of dexamfetamine has the same active ingredient and strength as the ‘PSM’ brand of dexamfetamine.
What does this mean for people taking dexamfetamine?
People using dexamfetamine (currently the ‘PSM’ brand) will need to change to the Aspen brand, likely during August or September. We acknowledge that a brand change for this medicine may be hard for some people. Our clinical experts have advised us that ongoing supply of dexamfetamine is essential which is why we’ve sourced another brand.
The packaging and tablets will look different, but the ‘Aspen’ brand has the same active ingredient and is the same strength.
We will keep this information from Pharmac, regarding Dexamfetamine, updated as we receive further information from Pharmac - ADHD New Zealand
API supplied around 21 funded medications in New Zealand, including dexamfetamine 5 mg tablets.
We expect stock of the API brand of dexamfetamine to begin running out during August 2022, and people will need to change brands to continue with their treatment. We know that a brand change for this medicine is not ideal. However, our clinical experts have advised us that ongoing supply of dexamfetamine is essential.
What we are doing
Pharmac is working to secure long-term supply of dexamfetamine sulfate 5 mg tablets. We will keep you updated about this, but in the meantime, we are listing a short-term supply of Aspen’s brand of dexamfetamine 5 mg tablets on the Pharmaceutical Schedule from 1 August 2022.
This brand of dexamfetamine has the same active ingredient and strength as the ‘PSM’ brand of dexamfetamine.
What does this mean for people taking dexamfetamine?
People using dexamfetamine (currently the ‘PSM’ brand) will need to change to the Aspen brand, likely during August or September. We acknowledge that a brand change for this medicine may be hard for some people. Our clinical experts have advised us that ongoing supply of dexamfetamine is essential which is why we’ve sourced another brand.
The packaging and tablets will look different, but the ‘Aspen’ brand has the same active ingredient and is the same strength.
We will keep this information from Pharmac, regarding Dexamfetamine, updated as we receive further information from Pharmac - ADHD New Zealand
